Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's Acquisition of Dionex Clears Antitrust Waiting Period

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Thermo Fisher Scientific said today that its proposed $2.1 billion acquisition of chromatography firm Dionex has cleared the mandatory, pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Thermo said it is in the process of "seeking similar clearances under antitrust laws of other jurisdictions," and expects to complete the acquisition later in the quarter.

The company in December announced plans to acquire Dionex for $118.50 per share in cash, which represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

Dionex shares were trading at $117.95 Monday afternoon.